Extended Data Fig. 4: Participant selection, baseline characteristics, and safety for belvarafenib phase I study.

a, b, Flow diagram indicating selection of study participants for dose-escalation (a) and dose-expansion (b) phases. In the dose-escalation phase (a), the full analysis set (FAS) included 67 out of 72 patients. Five patients without any post-dose tumour response assessments due to withdrawal of consent (n = 2), adverse event (n = 2), or progression of disease or lack of treatment effect (n = 1) were excluded from the FAS. In the dose-expansion phase (b), FAS included 59 out of 63 patients. Four patients without any post-dose tumour response assessments due to violation of inclusion/exclusion criteria (n = 1) or confirmed progressive disease or lack of efficacy in the judgement of the investigator (n = 3) were excluded from the FAS. QD, once daily; DLT, dose-limiting toxicity. c, Patient demographics and baseline characteristics. ECOG, Eastern Cooperative Oncology Group; GIST, gastrointestinal stromal tumour. d, Overall safety summary and treatment-emergent adverse events occurring in >10% of patients. TEAE, treatment-emergent adverse event. Result analysed with pooled data from dose-escalation and dose-expansion phases.